On November 17, 2026 Vittoria Biotherapeutics, Inc. reported that results from the Phase 1 VIPER-101 study of Senza5 CART5 in relapsed or refractory T-cell lymphoma will be presented in an oral session, and preclinical data on its LampTAC protein degradation platform will be presented in a poster session at the 68th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition, taking place December 12–15, 2026, in New Orleans, Louisiana.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The oral presentation will highlight clinical activity, CAR-T persistence, immune reconstitution, and delayed immune-mediated adverse events in heavily pre-treated patients with relapsed or refractory T-cell lymphoma. The presentation follows Vittoria’s announcement of U.S. Food and Drug Administration (FDA) Regenerative Medicine Advanced Therapy (RMAT) designation for Senza5 CART5, which was supported by this dataset, in addition to Orphan Drug designation.
"The responses we have seen in VIPER-101 strengthen our conviction that Senza5 CART5 can become a meaningful option for patients with relapsed or refractory T-cell lymphoma, who today have few effective choices," said Nicholas A. Siciliano, Ph.D., Chief Executive Officer of Vittoria Biotherapeutics.
A separate poster will describe LampTAC, a modular, genetically encoded protein degradation platform that enables cell-intrinsic protein control without genome editing and presents data supporting its potential for armoring in vivo CAR-T cells. Together, the presentations reflect Vittoria’s progress in building next-generation immunotherapies with a shared foundation in T-cell biology.
"Our work on CD5 has shown that modulating T-cell signaling pathways can make engineered T cells more potent. LampTAC is the evolution of that finding: a programmable, cell intrinsic protein degrader technology that can enhance in vivo engineered cells without genome editing. We look forward to presenting both datasets at ASH (Free ASH Whitepaper), and to advancing the distinct opportunities each represents," added Dr. Siciliano.
ASH 2026 Presentation Highlights and Details
VIPER-101 – Oral Presentation
Presentation title: High complete response rates, durable CD5-negative T-cell persistence, and mechanistically tractable delayed immune-mediated toxicity after low-dose CD5-edited CD5 CAR T-cell therapy in relapsed/refractory T-cell lymphoma
Presenter: Stefan K. Barta, M.D., M.S., Penn Medicine
Session: 625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Cellular and Immune Therapies in T-Cell and NK-Cell Malignancies
Abstract / publication number: 908
Date, time and location: Monday, December 14, 2026; 3:00 to 3:15 PM CT (session 2:45 to 4:15 PM); Ernest N. Morial Convention Center, New Orleans Theatre B
LampTAC – Poster Presentation
Presentation title: LAMPTAC: A genetically encoded lysosome-targeting chimera platform for programmable, cell-intrinsic protein degradation can enable multiplexed engineering of in vivo CAR-T cells for heme indications
Session: 702. CAR-T Cell Therapies: Basic and Translational: Poster III
Abstract / publication number: 5902
Date, time and location: Monday, December 14, 2026; 6:00:00 – 8:00:00 PM CT; MCCNO – Hall F
(Press release, viTToria biotherapeutics, NOV 17, 2026, View Source [SID1234674901])